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Abstract 
A 12 month review of infants admitted with neonatal abstinence syndrome to a neonatal 
intensive care unit was undertaken. The relationship of maternal drug abuse to symptoms, 
the effectiveness of pharmacologic agents in controlling symptoms and the length of 
inpatient stay were investigated. 
A retrospective review of maternal and infant records was performed. Those infants with a 
serial Finnegan score greater than 8 were treated. Pharmacologic treatment was oral 
morphine sulphate (0.2mg 4-6 hourly), phenobarbitone (3-7mgs/kg/day), or combination of 
the above. 
43 infants were admitted to the hospital during the year. The average maternal age was 24.6 
years, (18-34 years). Drug use volunteered by the mothers was methadone alone in 6 cases, 
methadone and benzodiazepines in 14, methadone and heroin and benzodiazepines in 7, 
methadone and heroin in 10, heroin alone in 2, and other multiple drug use including oral 
morphine sulphate, dothiepin and cannabis in 4. Average gestational age was 40.3 (35-42 
weeks). The average birthweight was 2.81 kgs (1.89-3.91 kgs). Time to onset of withdrawal 
symptoms was 2.8 <1-13) days. The duration of pharmacologic treatment (oral morphine 
sulphate and/or phenobarbitone) was 21.8 (1-62) days. The total hospital stay for the 43 
infants was 1,011 days. 
This study confirms that polydrug abuse is the commonest type of drug abuse in Dublin, 
The duration of withdrawal symptoms is loosely related to drug type. but increasing 
duration of symptoms is noted for infants exposed to benzodiazepines. Our experience 
would favour the use of morphine sulphate to treat pure opiate withdrawal symptoms. Over 
the 12-month period, there was an average occupancy of 3 beds per day in the paediatric 
department. 
Introduction 
A newborn infant born to a mother dependent on opiates may develop signs of drug withdrawal, 
the Neonatal Abstinence Syndrome (N.A.S.)1. This study was prompted by the large increase in 
the number of infants born to drug addicted mothers admitted to the paediatric unit at the Rotunda 
Hospital. The extent of drug abuse in Ireland is difficult to quantify accurately2; it is an illegal 
activity and therefore it is difficult to obtain accurate prevalence rates. Criminal detection 
statistics and numbers presenting at drug treatment centres are the best sources of data. 
Continuing audit is important to document the changing drug habits of addicted mothers, and the 
implications of the ensuing workload on limited hospital resources. 
Methods 
A retrospective review of all infants admitted with NAS from 1st January to 31st December 1996 
was performed. Those infants with mild withdrawal symptoms not requiring pharmacologic 
intervention were excluded. All babies were monitored clinically and symptoms were recorded 
objectively using the Finnegan Drug Withdrawal Score3. The decision to start pharmacology; 
treatment for N.A.S, was made by the paediatric registrar on duty based on the Finnegan score1.  
If scores were <8 for 3 days, maintenance dose was reduced by 10-15% per day. Pharmacologic 
treatment was discontinued when the infants clinical condition was stable on daily dosing of 
medicine. 
 
Data collected included maternal age, drugs abused, gestation, birth weight, duration of N.A.S, 
and agents used to control withdrawal symptoms. The duration of N.A.S. was defined as the 
period for which phenobarbitone and/or oral morphine sulphate were required to control 
withdrawal symptoms. 
Results 
During the one year period reviewed. 43 newborn infants with NAS were admitted to the 
Paediatric Department. A further 7 infants did not require admission nor pharmacologic 
intervention and these were excluded from the review. 
The average maternal age was 24.6 (18 to 34 years). Table I shows the drug use volunteered by 
the 43 mothers. The most common drug used was methadone. No distinction was made between 
smoking or injecting of heroin. The drugs abused in the “multiple” group include oral morphine 
sulphate, cannabis, dothiepin, Prothiaden® and diazepam. 
The average gestation of infants admitted was 40.3 (35-42 weeks) 




Methadone + Heroin 10 
Methadone + Benzodiazepines 14 
Methadone + Heroin + Benzodiazepines 7 
Multiple 4 
 n = 43 
with a mean birth weight of 2.81 (1.89-3.91 kgs). The birthweights of 11 of the infants were less 
than 2.5 kg and 15 weighed less than the 10th percentile for gestation. The average weight loss 
during the admission was 7.2% of the birth weight (1.2%-16%). Infants at discharge were 10% 
above their birth weight on average (0.34%). The mean time to onset of withdrawal symptoms 
was 2.8 (1 to 13) days; one baby was admitted on day 13 with irritability, jitteriness and poor 
feeding. The mean duration of N.A.S. was 21.8 (1-62) days. Table 2 illustrates the duration of the 
N.A.S. More than 50% of babies stayed for 15 to 28 days, while one stayed for a total of 62 days. 
Table 2 Duration of N.A.S.; length on pharmacologic treatment. 
 No. % 
7 – 14 9 21 
15 – 28 26 60 
29 – 42 4 9 
43 – 56 3 7 
>56 days 1 2 
Total 43 
Figure 1 shows the duration of N.A.S. in relation to the drugs abused. Infants stayed seven days 
longer in the benzodiazepine group compared to those taking methadone alone, the latter required 
least pharmacological support. Agents used to treat N.A.S. included a loading dose of 
phenobarbitone (10-20mg/kg/day) and a maintenance dose titrated using the Finnegan score. 
During the second six month period oral morphine sulphate (0.2mg four hourly initially and then 
 
gradually reducing) was given to infants of mothers taking opiates only. The average duration of 




introduction of oral morphine sulphate. Six infants required both phenobarbitone and oral 
morphine sulphate. The average duration of N.A.S. in this group was 16 days. The total inpatient 
stay for the study group was 1011 days. This approximates to almost 3 hospital bed-years or 3 
bed spaces occupied continuously over a one year period. 
Discussion 
Polydrug abuse is prevalent in the Dublin population studied here. Preliminary figures for 1995 
show that the total number of cases presenting for drug treatment in the greater Dublin area was 
3,593,2 Estimates suggest there are 8,000 heroin addicts in Dublin, 2.500 of who are willing to go 
on methadone programmes. The 15 to 24 years age group account for 64% of the total number 
receiving treatment2. The Ministerial Report published in October 1996 on measures to reduce the 
demand for drugs in Dublin, observed a 20% increase in 1995 in those attending for drug 
treatment compared to 1994. 
Perinatal mortality in the pregnant drug abusing population is increased, mainly because of an 
increase in delivery of low birth weight infants.4 The largest reported experience in managing 
babies comes from the United States. There are marked differences in Ireland in the drugs abused, 
in the abusers lifestyles and in the social supports available. The prevalence of cocaine abuse in 
the pregnant population ranges from 6 to 27%, Bosio et al detected one case of cocaine abuse in 
504 antenatal patients5. 
Increasing drug abuse is a worldwide phenomenon6. A quarter of drug abusers are female, almost 
all of child bearing age2. As N.A.S. is associated with intra uterine growth retardation, placental 
insufficiency and foetal distress, its effect on long term foetal outcome is unclear. A further 
compounding factor effecting follow up studies are poor social circumstances. The social work 
department monitors the mothers through the antenatal period, arranges weekly interviews during 
the abstinence period and sees the parents fortnightly during the initial discharge period. In our 
study most infants were discharged home with their mothers, almost always after a case 
 
conference was held. 
Infants of drug abusers have an increased risk of sudden infant death6, developmental delay and 
poor school performance7. At 18 months only 81% in one study were living with their parents, 
highlighting the broader social implications8. Most reviews note an increase in neurologic 
abnormalities, e.g. muscle tone discrepancies, articulation disorders, as well as weak visual, 
motor and perceptual skills. Lower Bayley developmental scores9 have been attributed to lack of 
stimulation and genetic factors, as well as drug effects. Infants of women abusing opiates during 
pregnancy appear to have attachment difficulties e.g. behavioural problems, inattention. 
disorganisation and distractibility, and are ultimately at risk of child abuse and neglect12. 
However a recent study showed no significant difference in development of children born to drug 
abusing mothers8. These young mothers may go on to a further pregnancy and should be educated 
about the risks of drug abuse. In our study Hepatitis C serology was available on 32 mothers. 21 
of these mothers (65.6%) were positive for hepatitis C. Two mothers had evidence of HIV and 
one of Hepatitis B infection. All of these infants were protected by maternal antibody as none to 
date have evidence of HIV/Hepatitis C infection. The infants were not routinely immunised 
against Hepatitis B. Preventive measures should include school education programmes, health 
promotion strategies and treatment services10. A collaborative community health, obstetric and 
paediatric approach should heighten awareness of attendant risks and reduce the incidence, 
severity and duration of N.A.S. 
A retrospective study relies on accurate history taking and urinalysis. A recent Irish study of 
chemical substance abuse in an obstetric population found that none of the women found positive 
on urinalysis had been identified on history alone.5 Moreover, single urinalysis screening is of 
limited value and serial screening of high-risk mothers should improve identification. Toxicologic 
screening of urine was not performed routinely in this group. N.A.S. typically presents within 
four days of delivery but may be present at birth11. Symptoms may not however appear until 
much later11 as seen in our study. Shaw et al in Liverpool advocate discharge after three days if 
no major signs of withdrawal are observed1. In the present study the shortest withdrawal periods 
were seen in infants exposed to methadone only and the longest stay occurred with heroin. This 
contrasts with other studies12. This surely reflects two ends of the spectrum from compliance with 
a methadone programme through to the worst scenario of abusing street drugs. Maternal 
methadone doses of less than 20mg daily are associated with mild withdrawal symptoms and this 
is a therapeutic aim in many drug addiction centres6. Infants stayed longer in the benzodiazepine 
groups13 compared to those taking methadone alone, underlining the unsuitability of these drugs 
for the pregnant addict. 
Treatment of the neonate should be primarily supportive as unjustified pharmacologic 
administration will prolong hospitalisation11. Supportive care includes swaddling to decrease 
sensory stimulation, frequent small feeds, high calorie low birth weight formula feeds, and 
observation of sleeping habits, temperature, weight gain or loss, and change in symptomatology 
which might suggest another diagnosis, e.g. sepsis. Nursing care and other activities should be 
organised to allow uninterrupted rest periods. Pacifiers for non-nutritive sucking are beneficial. 
Suppression of the centrally excited noradrenergic cells can be achieved with morphine or 
phenobarbitone, the objective being to control withdrawal signs with avoidance of side-effects, 
Phenobarbitone, however, by virtue of its long acting nature may depress sucking behaviour. In 
order to achieve equivalent receptor mediated cell suppression and a more gradual withdrawal, 
infants exposed to maternal heroin or methadone should receive an opiate such as oral morphine 
sulphate. The targeting of pure opiate withdrawal with oral morphine sulphate in this study 
reduced hospital stay. The infants were seen weekly at a consultant clinic in the initial discharge 
period and monthly thereafter. 
 
 An additional £9 million was made available in 1996 for the management of drug addiction in the 
community, a clear acknowledgement of the problem. There are concomitant implications for the 
neonatal and maternity services: over the 12 month period studied, 8.3% of the total bed 
occupancy and 3.5% of all paediatric admissions were occasioned by N.A.S. at the Rotunda 
Hospital. Staffing and resources need to be increased, if the needs of the most vulnerable victims 
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